二甲双胍的药物遗传学
二甲双胍虽是2型糖尿病一线用药,但并非人人有效;因作用机制未明,难以识别应答者。候选基因研究提供部分线索,全基因组关联研究正提供不受先验知识限制的新发现;实现潜力需通过国际协作纳入更大样本。
要点
- 二甲双胍并非对所有2型糖尿病患者均能最优起效。
- 候选基因研究已揭示遗传变异对二甲双胍应答的部分影响。
- 全基因组关联研究可提供不受先验知识限制的新见解。
核心结论
- 阐明二甲双胍应答者与非应答者受限于对其精确分子作用机制认识不足。
- 全基因组关联研究正开始提供不受先验知识限制的额外见解。
研究设计与样本
- 采用无先验假设的全基因组方法,在规模适当的队列中部署以达到足够统计效能。
- 通过国际协作组装更大样本,最好涉及学术界、政府和制药行业。
主要发现
- 候选基因研究已为遗传变异影响二甲双胍应答提供部分线索。
- 全基因组关联研究正开始提供不受先验知识限制的额外见解。
临床怎么用
- 原文未据此给出推荐。
局限性
- 对二甲双胍精确分子作用机制认识有限,妨碍识别可能应答者与非应答者。
- 需通过国际协作组装更大样本以充分发挥全基因组关联研究潜力。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Despite its widespread use as the first-line agent for the treatment of type 2 diabetes, it has become clear that metformin does not work optimally for everyone. Elucidating who are the likely metformin responders and non-responders is hampered by our limited knowledge of its precise molecular mechanism of action. One approach to achieve the related goals of stratifying patients into response subgroups and identifying the molecular targets of metformin involves the deployment of agnostic genome-wide approaches in cohorts of appropriate size to attain sufficient statistical power. While candidate gene studies have shed some light on the role of genetic variation in influencing metformin response, genome-wide association studies are beginning to provide additional insight that is unconstrained by prior knowledge. To fully realise their potential, much larger samples need to be assembled via international collaboration, preferably involving the academic community, government and the pharmaceutical industry.
引用
- Florez JC. The pharmacogenetics of metformin. Diabetologia. 2017. PMID: 28770331. doi:10.1007/s00125-017-4335-y
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。